Abstract
Glutamic acid decarboxylase (GAD) is the enzyme which catalyzes the production of gamma aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system (CNS). There is increasing evidence that severe GAD autoimmunity may be associated with refractory epilepsy. Immunomodulation and GABAergic drugs have been suggested as treatment options. We report here for the first time on a patient with sudden onset of refractory status epilepticus in the presence of strong intrathecal anti-GAD antibody synthesis who was successfully treated with cyclophosphamide, and give an overview of available data on epilepsy associated with GAD autoimmunity.
MeSH terms
-
Adult
-
Antibodies, Anti-Idiotypic / biosynthesis
-
Antibodies, Anti-Idiotypic / drug effects*
-
Antibodies, Anti-Idiotypic / immunology
-
Anticonvulsants / therapeutic use
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / immunology
-
Autoimmunity / immunology
-
Brain / diagnostic imaging
-
Brain / pathology
-
Cyclophosphamide / therapeutic use*
-
Drug Resistance
-
Epilepsy, Complex Partial / drug therapy
-
Epilepsy, Complex Partial / immunology
-
Female
-
Glutamate Decarboxylase / immunology*
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / therapeutic use*
-
Injections, Spinal
-
Magnetic Resonance Imaging
-
Status Epilepticus / drug therapy*
-
Status Epilepticus / immunology*
-
Status Epilepticus / pathology
-
Tomography, Emission-Computed, Single-Photon
Substances
-
Antibodies, Anti-Idiotypic
-
Anticonvulsants
-
Immunosuppressive Agents
-
Cyclophosphamide
-
Glutamate Decarboxylase